Orforglipron: The First GLP-1 Pill

A small-molecule, non-peptide GLP-1 receptor agonist taken as a daily pill — no injections, no food or water restrictions. Approved by the FDA on April 1, 2026 under the brand name Foundayo for chronic weight management.

🔬 Orforglipron is the first GLP-1 you can swallow. That alone reframes the obesity-drug supply chain — no cold chain, no injection training, no fill-finish bottleneck. Whether it matches injectable efficacy is the open question.

Mean Body Weight
Loss (ATTAIN-1)

Days From Filing
to FDA Approval

Oral Pill
(No Injection)

Mechanism of Action

How It Works

💊

Oral Small-Molecule

Non-peptide GLP-1 receptor agonist — survives digestion intact. No injection, no SNAC absorption enhancer required (unlike Rybelsus oral semaglutide).

🧬

GLP-1R Selective

Activates glucagon-like peptide-1 receptors on pancreatic beta cells (insulin release) and CNS appetite centers. Slows gastric emptying.

🍽️

No Food/Water Rules

Unlike Rybelsus (must take fasted with ≤120 mL water), orforglipron has no food or water restrictions. Take any time of day.

📅

Once-Daily Titration

Start 3 mg, titrate every 4 weeks: 3 → 6 → 12 → 24 → 36 mg. Maximum maintenance dose 36 mg/day. Half-life ~30 hours.

Data

What the Data Shows

Mean Body Weight Loss (ATTAIN-1, 36 mg)

Phase 3 obesity trial, 72 weeks vs placebo

14.5%

A1C Reduction (ACHIEVE-1, 36 mg)

T2D trial, 40 weeks

−2.0%

Placebo Weight Loss (Comparator)

ATTAIN-1 placebo arm

~2%

Patients Reaching ≥5% Weight Loss

36 mg arm at 72 weeks

~70%

Patients Reaching ≥10% Weight Loss

36 mg arm at 72 weeks

~50%

Bottom Line

Key Takeaways

✅ What We Know

First non-peptide oral GLP-1 receptor agonist — no injection
FDA-approved April 1, 2026 as Foundayo for chronic weight management (obesity or overweight + comorbidity)
ATTAIN-1 phase 3: ~14.5% mean body-weight loss at 36 mg / 72 weeks
A1C reduction ~2.0% in T2D trial ACHIEVE-1 at top dose
No food, water, or timing restrictions (unlike Rybelsus)
GI side-effect profile similar to other GLP-1s: nausea, diarrhea, vomiting (mostly during titration)
Approved under FDA Commissioner’s National Priority Voucher pilot — fastest NME approval on record (50 days)

⚠️ What We Don't Know

Long-term cardiovascular outcome data still maturing
Direct head-to-head vs tirzepatide injectable not yet published
Real-world adherence data (vs once-weekly injection) — too early to know
Pediatric and adolescent indications not yet approved
Pricing and insurance coverage post-launch is in flux

FAQ

Frequently Asked Questions

What is orforglipron and what is it used for?

Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly under the brand name Foundayo. The FDA approved it on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity. It is the first non-peptide oral GLP-1 — the prior oral GLP-1, Rybelsus, is peptide-based and requires absorption enhancers and strict food/water restrictions.

How does orforglipron compare to Ozempic, Wegovy, and Mounjaro?

In phase 3 ATTAIN-1, orforglipron at 36 mg achieved ~14.5% mean body weight loss at 72 weeks. That is roughly comparable to semaglutide 2.4 mg (Wegovy: ~15%) but below tirzepatide 15 mg (Zepbound: ~21%) and retatrutide 12 mg (~24% in phase 2). The big differentiator is route of administration: a daily pill instead of a weekly injection, with no food or water restrictions.

What is the dosing schedule?

Once-daily oral, titrated every 4 weeks: 3 mg → 6 mg → 12 mg → 24 mg → 36 mg. Maximum maintenance dose is 36 mg/day. Slow titration manages GI side effects.

What are the side effects?

Most common: nausea, diarrhea, vomiting, decreased appetite, constipation — typical of the GLP-1 class. Most occur during dose titration and resolve with continued use. Black-box warning for thyroid C-cell tumors based on rodent data, consistent with other GLP-1s. Pancreatitis and gallbladder events are rare but documented.

How was it approved so fast?

Orforglipron was the first new molecular entity approved under the FDA Commissioner's National Priority Voucher (CNPV) pilot program — 50 days from filing to approval, a record for the agency.